Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Available 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Myeloid 4Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia, Myeloid, Acute 183Precursor Cell Lymphoblastic Leukemia-Lymphoma 109Hematologic Neoplasms 91Leukemia, Lymphocytic, Chronic, B-Cell 88Myelodysplastic Syndromes 70Leukemia 59Lymphoma 44Multiple Myeloma 40Lymphoma, Non-Hodgkin 36Leukemia, Myelogenous, Chronic, BCR-ABL Positive 34Burkitt Lymphoma 27Recurrence 23Neoplasms 22Leukemia, Myelomonocytic, Chronic 21Myeloproliferative Disorders 20Hodgkin Disease 20Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 19Lymphoma, Large B-Cell, Diffuse 19Leukemia, Biphenotypic, Acute 18Lymphoma, Mantle-Cell 17Leukemia, B-Cell 16Lymphoma, B-Cell 15Lymphoma, Follicular 14Waldenstrom Macroglobulinemia 13Anemia, Refractory, with Excess of Blasts 13Myelodysplastic-Myeloproliferative Diseases 11Lymphoma, B-Cell, Marginal Zone 11Leukemia, Hairy Cell 9Blast Crisis 9Primary Myelofibrosis 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Mastocytosis, Systemic × Other hematologic neoplasm × 30 days × Clear all
NCT06915766 2026-05-28

Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis

Cogent Biosciences, Inc.

Available
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Mastocytosis, Systemic

NCT05362773 2026-05-22

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

MacroGenics

Phase 1 Recruiting
130 enrolled
LymphoidMyeloidOther hematologic neoplasm

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Hairy Cell, Myelodysplastic Syndromes, Leukemia, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡